The CSL Ltd (ASX: CSL) share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there’s a chance that the ASX healthcare share could recover a lot of the lost ground.
The global biotech business provides a number of healthcare products, including blood plasma-related treatments and vaccines.
UBS recently released a note that outlined one of the reasons why investors can be excited by the business.
Image source: Getty Images
UBS is positive on the biotech giant
The broker said that there has been a rapid uptake of CSL’s Andembry since the launch in mid-2025, with more than 1,000 patients on the therapy. UBS estimates this is around 15% of patients…
